Safety Reading Notes

Read safety context beside the research guide.

The TRPM8 cannabinoid target source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 18354058

PubMed For Dummies Article

TRPM8 cannabinoid target Evidence Review: the long-form source walk-through

Quick read
  • TRPM8 cannabinoid target currently has 15 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 18354058
  • The evidence classes most visible in the row language are mechanistic or pharmacological (8), and insufficient (7). PMID 35483477
  • The study-design language most visible in the row language is Narrative or expert review (5), Animal study (5), Systematic review (1), and other mapped categories (1). PMID 21175579
  • The repeated topics are TRPM8 (15), which tells the reader where to start opening PubMed and DOI links. PMID 25269802

Start with the research question

TRPM8 cannabinoid target is built from 15 source-backed evidence row(s) and 15 research source(s). The current evidence classes read as mechanistic or pharmacological (8), and insufficient (7), and the study-design language most often reads as Narrative or expert review (5), Animal study (5), Systematic review (1), and other mapped categories (1). PMID 18354058

The row-level question is not simply whether TRPM8 cannabinoid target is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are TRPM8 (15). PMID 35483477

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 40540228

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 29240420

Mechanistic evidence 8 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 19070372

Limits and uncertainty 7 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 29470146

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 28120232

Where this page has the most source density

The largest bucket surfaced for this page is TRPM8: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is TRPM8: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 18354058

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 35483477

Bucket chapters: what the literature is circling

TRPM8: mechanistic or pharmacological

8 research sources 8 rows (1049-1062) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on TRPM8: mechanistic or pharmacological. It currently draws from 8 research source(s), so the exact study type matters. PMID 18354058

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 18354058

  • Evidence row 1049

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 18354058

  • Evidence row 1062

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 30077611

TRPM8: insufficient

7 research sources 7 rows (1048-1060) Evidence class: insufficient

This bucket summarizes source-backed rows focused on TRPM8: insufficient. It currently draws from 7 research source(s), so the exact study type matters. PMID 35483477

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 35483477

  • Evidence row 1048

    CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35483477

  • Evidence row 1060

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21622235

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (8 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 18354058

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 35483477

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 35605018
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 38408345
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 39684707

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 18354058

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 35483477

Source-reading checklist for TRPM8 cannabinoid target

  1. Open the linked PubMed or DOI record. PMID 21622235
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 17428469
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 30077611
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 18354058
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 35483477

Source Notes

TRPM8 cannabinoid target source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1048

    CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35483477

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
  2. Evidence row 1049

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 18354058

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
  3. Evidence row 1050

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  4. Evidence row 1051

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 25269802

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
  5. Evidence row 1052

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 40540228

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
  6. Evidence row 1053

    THC modulates TRPM8; evidence class: insufficient (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 29240420

    Evidence class: insufficient. Source: Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids.
  7. Evidence row 1054

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 19070372

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
  8. Evidence row 1055

    Cannabinoids modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 29470146

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
  9. Evidence row 1056

    THC modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 28120232

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Targets of the Phytocannabinoids: A Complex Picture.
  10. Evidence row 1057

    CBD modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35605018

    Evidence class: insufficient; Study design: Systematic review. Source: Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward.
  11. Evidence row 1058

    CBD modulates TRPM8; evidence class: mechanistic or pharmacological (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 38408345

    Evidence class: mechanistic or pharmacological. Source: Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV.
  12. Evidence row 1059

    Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 39684707

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.
  13. Evidence row 1060

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21622235

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Effects of opioids, cannabinoids, and vanilloids on body temperature.
  14. Evidence row 1061

    Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 17428469

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.
  15. Evidence row 1062

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 30077611

    Evidence class: mechanistic or pharmacological. Source: Iodine-mediated cyclization of cannabigerol (CBG) expands the cannabinoid biological and chemical space.